Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia
Completed
- Conditions
- Dyslipidaemia
- Registration Number
- NCT01221584
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/ the 4th Joint European Task Force guidelines.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- Subject must be 18 years of age or older of either gender or race.
- Subject must provide informed consent and comply with the survey procedures.
- Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
Exclusion Criteria
- Subjects who are unwilling or unable to provide informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/the Fourth Joint European Task Force guidelines 1 visit - 1-3 days
- Secondary Outcome Measures
Name Time Method Establish the proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines in the sub-population patients with fasting triglycerides >200 mg/dL (2.26mmol/L) 1 visit - 1-3 days Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Russian guidelines in the following sub-populations: Primary/secondary prevention patients, Patients with metabolic syndrome 1 visit - 1-3 days Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the FJETF/ NCEP ATP III guidelines, in all population and in Primary/secondary prevention patients, Patients with metabolic syndrome 1 visit - 1-3 days
Trial Locations
- Locations (1)
Research Site
🇷🇺Yaroslavl, Russian Federation